The impact of regular sauerkraut consumption on the human gut microbiota: a crossover intervention trial

Microbiome, Год журнала: 2025, Номер 13(1)

Опубликована: Фев. 12, 2025

Язык: Английский

---

Fecal Microbiota Characteristics in Constipation-Predominant and Mixed-Type Irritable Bowel Syndrome

Microorganisms, Год журнала: 2024, Номер 12(7), С. 1414 - 1414

Опубликована: Июль 12, 2024

Irritable bowel syndrome (IBS) is a common condition that affects the lifestyle of patients. It associated with significant changes in composition gut microbiome, but underlying microbial mechanisms remain to be fully understood. We study fecal microbiome patients constipation-predominant IBS (IBS-C) and mixed-type (IBS-M).

Язык: Английский

---

High-dose dual therapy for Helicobacter pylori eradication inducing less impact on the gut microbiota

Gut Pathogens, Год журнала: 2025, Номер 17(1)

Опубликована: Янв. 30, 2025

Язык: Английский

---

Captive environments reshape the compositions of carbohydrate active enzymes and virulence factors in wolf gut microbiome

BMC Microbiology, Год журнала: 2025, Номер 25(1)

Опубликована: Март 15, 2025

Язык: Английский

---

Positive nutritional selection of adults with healthy lifestyle and high daily fiber consumption for the isolation of beneficial intestinal bacteria: the iTARGET cohort study protocol.

MethodsX, Год журнала: 2025, Номер unknown, С. 103268 - 103268

Опубликована: Март 1, 2025

Recent advances in the study of gut microbiota has pointed to its under-utilized source potentially beneficial bacteria, known as next generation probiotics, offering a promising avenue restore or compensate impaired toward healthy state. Aside from difficulties achieve in-lab adequate culture conditions, use bacterial isolates is also limited by their bioavailability donor itself. In iTARGET study, we positively selected donors based on diet enriched fiber, that been shown increase prevalence species associated with health. The monocenter, prospective, observational adults lifestyle and high daily fiber consumption. We aim recruit individuals two phases, first one for all will permit identification carriers bacteria interest second phase subset allow isolation previously identified bacteria. Our primary outcome at least isolate. secondary outcomes comprised throughput metagenomic profiles intestinal characterization cultured isolates. was approved French Research Ethics Committees (Comité de Protection des Personnes Sud-Est I) under National reference ID 2023-A01677-38. Study findings results be published peer-reviewed Open Access journals. (Trial registration number ClinicalTrials.gov: NCT06166810).

Язык: Английский

---

The effects of probiotic treatment with Bifidobacterium breve, Bif195 for small intestinal Crohn’s disease and the gut microbiome: results from a randomised, double-blind, placebo-controlled trial

Gut Pathogens, Год журнала: 2025, Номер 17(1)

Опубликована: Апрель 9, 2025

Язык: Английский

---

Expansion of a bacterial operon during cancer treatment ameliorates fluoropyrimidine toxicity

Science Translational Medicine, Год журнала: 2025, Номер 17(794)

Опубликована: Апрель 16, 2025

Dose-limiting toxicities remain a major barrier to drug development and therapy, revealing the limited predictive power of human genetics. Here, we demonstrate utility more comprehensive approach studying toxicity through longitudinal profiling gut microbiome during colorectal cancer (CRC) treatment (NCT04054908) coupled cell culture mouse experiments. Substantial shifts in microbial community structure oral fluoropyrimidine across multiple patient cohorts, small large intestinal contents, patient-derived ex vivo communities were revealed by 16 S rRNA gene sequencing. Metagenomic sequencing marked pyrimidine-related abundance treatment, including enrichment preTA operon, which was sufficient for inactivation active metabolite 5-fluorouracil (5-FU). + bacteria depleted 5-FU microbiota grown distal gut. Germ-free antibiotic-treated mice experienced increased toxicity, rescued colonization with microbiota, Escherichia coli , or -high stool from patients CRC. Last, negatively associated patients. Together, these data support causal, clinically relevant interaction between bacterial operon dose-limiting side effects treatment. Our may be generalizable other drugs, immunotherapies, provides valuable insights into host-microbiome interactions context disease.

Язык: Английский

---

Dynamic causal effects of gut microbiota on cervical Cancer lesion progression

Scientific Reports, Год журнала: 2025, Номер 15(1)

Опубликована: Май 3, 2025

Язык: Английский

---

Expansion of a bacterial operon during cancer treatment ameliorates drug toxicity

bioRxiv (Cold Spring Harbor Laboratory), Год журнала: 2024, Номер unknown

Опубликована: Июнь 6, 2024

Abstract Dose-limiting toxicities remain a major barrier to drug development and therapy, revealing the limited predictive power of human genetics. Herein, we demonstrate utility more comprehensive approach studying toxicity through longitudinal study gut microbiome during colorectal cancer (CRC) treatment ( NCT04054908 ) coupled cell culture mouse experiments. 16S rRNA gene metagenomic sequencing revealed significant shifts in microbial community structure with oral fluoropyrimidines, which was validated an independent cohort. Gene abundance also markedly changed by including enrichment for preTA operon, is sufficient inactivation active metabolite 5-fluorouracil (5-FU). Higher levels led increased 5-FU depletion microbiota grown ex vivo . Germ-free antibiotic-treated mice had fluoropyrimidine toxicity, rescued colonization microbiota, + E. coli , or CRC patient stool high levels. negatively associated toxicities. Together, these data support causal, clinically relevant interaction between bacterial operon dose-limiting side effects treatment. Our generalizable other drugs, immunotherapies, provides valuable insights into host-microbiome interactions context disease. One Sentence Summary Gut enzymes can be used predict prevent anticancer toxicity.

Язык: Английский

---

Role of immune cells in mediating the effect of gut microbiota on Hashimoto’s thyroiditis: a 2-sample Mendelian randomization study

Frontiers in Microbiology, Год журнала: 2024, Номер 15

Опубликована: Окт. 14, 2024

Purpose Hashimoto’s thyroiditis (HT) is one of the most commonly encountered types autoimmune thyroid disorders (AITDs), influenced by environmental factors, genetics, and immune system. Previous research has shown a correlation between gut microbiota HT, as well involvement cells in its onset progression. We aimed to investigate whether act intermediaries causal relationship HT. Methods In this study, we conducted bidirectional two-sample Mendelian randomization (MR) analyses explore HT using data from genome-wide association studies (GWAS) MiBioGen study. Subsequently, MR were performed interactions 731 microbiota. Additionally, an analysis was examine these cells, GWAS dataset that included 3,757 European subjects. This approach provided insights into impact 22 million genetic variants on cell signatures. Results There increase number 15 observed genus Akkermansia , family Alcaligenaceae, Desulfovibrionaceae, Verrucomicrobiaceae, class Verrucomicrobiae, order Verrucomicrobiales, phylum Verrucomicrobia, Alphaproteobacteria, Desulfovibrionales, Ruminococcus torques group, Butyrivibrio Coprococcus3 negatively correlated with addition, Intestinimonas Turicibacter Anaerostipes positively identified EM CD4 + T mediator Conclusion conclusion, presented associations cell-mediated inferred findings derived extensive aggregated data. Our offers guidance direction for treating preventing

Язык: Английский

---